NASDAQ · CING
Cingulate Inc.
$5.19-$0.06 (-1.14%)
Cingulate Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.35% below the high.
Loading market information…
NASDAQ · TRAW · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Traws Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.68% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Traws Pharma, Inc.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.21. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Traws Pharma, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $57.00K-5.0% vs estimate |
| Q4 2024 | Mar 31, 2025 | $0.96+1,101.68% vs estimate | $56.00K-6.67% vs estimate |
|---|
| Q2 2024 | Nov 15, 2024 | -$8.81-40.96% vs estimate | $57.00K-5.0% vs estimate |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $1.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$5.19-$0.06 (-1.14%)
Cingulate Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.35% below the high.
$1.23-$0.01 (-0.81%)
Dogwood Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.54% below the high.
$0.98-$0.01 (-1.01%)
Cocrystal Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.3% below the high.
$13.85-$3.97 (-22.28%)
Sensei Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.32% below the high.
$6.36-$0.22 (-3.34%)
Bolt Biotherapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 18.25% below the high.
$0.92+$0.02 (+2.48%)
Immuron Limited’s quoted price sits in the lower half of its reported 52-week range, 56.69% below the high.
$0.83+$0.00 (+0.35%)
Imunon, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.61% below the high.
$0.38+$0.01 (+1.6%)
Evogene Ltd.’s quoted price sits in the lower half of its reported 52-week range, 70.74% below the high.
